Major study shows adding therapy almost halves risk of stroke and other cardiovascular events
Dorval, Quebec - Data from the independent KYOTO HEART study shows that adding Diovan (valsartan) to conventional treat- ment to improve blood pressure control may improve cardiovascu-lar outcomes in patients with high blood pressure at high risk of car- diovascular events.
Presented recently at the European Society of Cardiology (ESC) Congress in Barcelona, Spain, and published online in the European Heart Journal, the study showed that Diovan* (val- sartan) added to conventional treatment, provided a significant 45% relative risk reduction in car- diovascular events,1 including stroke, compared to conventional treatment.1
“This study followed high risk patients commonly seen in clinical practice and while the results reinforce that getting blood pres- sure down is important, choosing the right treatment to get there is vital because some medicines have additional protective bene- fits, “ said Dr. Parmjit Sohal, MD, PhD, CCFP, FCFP, a family physi-cian and a clinical assistant pro- fessor at the University of British Columbia, Vancouver, B.C. Diovan* (valsartan) is an angiotensin II receptor blocker (ARB), which is a class of medica- tion used for controlling high blood pressure. It controls high blood pressure by blocking the action of angiotensin II. As a result, the blood vessels dilate and blood pressure is reduced. Details about the study A total of 3,031 Japanese patients with uncontrolled high blood pressure either with no treatment or on a previous non- RB-based regimen and with one or more pre-defined cardiovascu- lar risk factors (e.g. existing dia- betes, obesity, smokers, or a his- tory of cardiovascular disease) took part in the study. Patients were randomized to receive either additional treatment with Diovan* (valsartan) or a non-ARB conven- tional therapy.
The primary study endpoint was a composite of defined car- dio- and cerebrovascular events including stroke, myocardial infarction (heart attack), and hos- pitalization for heart failure or angina (chest pain).2 Compared with the non-ARB arm, fewer individuals in the valsartan arm reached the primary end- point.
The reduction in the compos-ite primary endpoint was largely due to a 45% reduction observed in the risk of stroke and a 49% reduction in the risk of angina.1 What does this mean for Indo-Canadians?
General changes in lifestyle throughout East Asia in recent years has resulted in the Japanese risk profile becoming more similar to that of other pop-lations. “KYOTO HEART enrolled patients with high rates of meta-bolic syndrome and obesity, and numerous smokers, “ said Dr. Sohal.
“For this reason, the results of this study may not only be rele- vant to patients with high blood pressure in Japan, but also other populations like Indo-Canadians where such risk factors are highly prevalent. ” The study was prematurely stopped after a median observa- tion time of 3.27 years. This was for ethical reasons because of unequivocal benefit in the Diovan* (valsartan) group.
More details on Diovan*
Approved in Canada in 1997, Diovan* (valsartan) is a selective ARB, and is indicated for the treatment of mild to moderate essential hypertension. Diovan* may be administered alone, or in combination with thiazide diuret- ics or as a fixed dose combination called Diovan*-HCT. Diovan* is also approved to reduce cardio-vascular mortality in clinically sta- ble patients with signs and symp- toms of left ventricular dysfunc- tion in conjunction with acute myocardial infarction when the use of an angiotensin-converting enzyme inhibitor (ACEI) is not appropriate. Diovan* is also approved for use in patients with chronic heart failure who have been shown to be intolerant to an angiotensin converting enzyme inhibitor. There is no evidence that Diovan* provides added ben- efits when it is used with ACE inhibitors. Diovan* is not approved to reduce the risk of stroke or angina pectoris.
About Novartis Pharma-ceuticals Canada
Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. Novartis Pharmaceu- ticals Canada Inc. conducts hun- dreds of clinical trials across the country seeking new treatments for cardiovascular disease, oncol- ogy, diabetes, cancer, ophthal- mology and organ transplanta- tion. In 2007, the Company invested close to $86 million in research and development. Novartis Pharmaceuticals Canada Inc. employs more than 800 peo- ple in Canada and its headquar- ters are located in Dorval, Québec. In addition to Novartis Pharmaceuticals Canada Inc., the Novartis Group in Canada consists of Novartis Animal Health Canada Inc., Novartis Consumer Health Canada Inc., CIBA Vision Canada Inc. and Sandoz Canada Inc. For further information about Novartis Canada, please consult www.novartis.ca *Diovan is a registered trade- mark